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Volume 53, Number 17S Abstracts 67Sand analyzed. Up to 2-year follow up was determined by
contacting patients or physicians working at rehabilitation
hospitals.
Results: Over this two-year period, 60 patients under-
went BKA (45 male, 15 female), with one patient having
bilateral BKAs The average age was 67 years (range 38-91).
Preoperatively, 33/61 were not able to walk. The indica-
tions for surgery was entirely for sepsis or ischemia, (61/61,
100%). Furthermore, 36/61 (58%) of the patients had
failure of a previous revascularization or more distal ampu-
tation, and 5/61 (8%) required an amputation despite a
patent bypass graft. Major co-morbidities were diabetes
(49/61, 80%) and chronic renal failure (25/61, 41%).
There were 4 perioperative deaths (6%). Seventeen (28%)
wound complications occurred, of which 14 (23%) re-
quired revision. The average length of stay before transfer
to a rehab facility was 25.6 days. During a follow up period
of two years, 25 patients (42%) died. Twelve patients were
lost to follow up. The average time to final prosthesis was
4.8 months. At one year post BKA, 33/35 (94%) patients
who were alive, were walking with their prosthesis, and
2/61 (3%) could not walk because of either a poorly fitting
prosthesis or poor wound healing.
Conclusions: When BKA is required for sepsis or isch-
emia; the vast majority of patients can expect to survive the
procedure. However, amputation revision is commonly
needed. The two-year survival is poor. Nonetheless, for
patients who tolerate amputation and survive at least two
years, ambulation with a walking prosthesis was seen in the
vast majority.
Author Disclosures: M. al-Ghamdi: Nothing to dis-
close; Y. N. Hsiang: Nothing to disclose; S. Ko: Noth-
ing to disclose; J. Poon: Nothing to disclose; H. Un-
derwood: Nothing to disclose; E. Weiss: Nothing to
disclose.
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Andrew Tye, Ageliki G. Vouyouka, Rami O. Tadros, Con-
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Objectives: This study assesses the influence of gender
on infrageniculate peripheral arterial disease (PAD) treated
percutaneously.
Methods: Sixty-one patients (30males and 31 females)
requiring infrageniculate interventions were studied. Males
and females were compared over 24 months. Statistical
analysis was conducted with SPSS software (SPSS Inc.
Chicago, IL).
Results: Females presented for treatment of infra-
geniculate PAD at a later age than males (75.6 vs. 67.5
years, p0.008) and were more likely to have co-morbid UOPD (p0.023). There were no differences in other
o-morbidities, rates of tissue loss or rest pain at presen-
ation, disease distribution, primary procedures per-
ormed, peri-procedural complications, lengths of stay
LOS), primary and secondary patency, limb salvage, or
ortality. However, males were more likely to undergo
imultaneous treatment of popliteal and tibial lesions
28.1% vs. 6.1%, p0.019) and were more likely to
equire a bypass after failed primary interventions (10.5%
s. 0.0%, p0.044).
Conclusions: The presentation and disease distribu-
ion of PAD are comparable among males and females.
elow-the-knee interventions are safe and effective in both
enders with similar overall outcomes. However, males
resent for treatment of infrageniculate PAD at an earlier
ge and are more likely to require a bypass after failed
rimary interventions.
uthor Disclosures: S. H. Ellozy: Nothing to disclose;
. L. Faries: Nothing to disclose; S. Kim: Nothing to
isclose; M. L. Marin: Nothing to disclose; C. T.
pyris: Nothing to disclose; R. O. Tadros: Nothing to
isclose; V. J. Teodorescu: Nothing to disclose; W.
ing: Nothing to disclose; A. Tye: Nothing to disclose;
. G. Vouyouka: Nothing to disclose.
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June Supplement 201168S AbstractsObjectives: The treatment of venous insufficiency us-
ing endovenous laser ablation (EVLA) results in variable
post-procedural symptomatology. Higher wavelength la-
sers selectively target the vein wall and may improve post-
procedural symptoms. This study sought to determine if
higher wavelength lasers result in diminished post-proce-
dural pain and bruising.
Methods: This study was a retrospective review of a
prospectivelymaintained database from12/2003 to 8/2010.
Patients undergoing EVLA of the great or small saphenous
veins were evaluated. Bare-tipped catheters using 810nm,
980nm, and 1320nm wavelengths were evaluated. The pri-
mary outcomes were average 7-day pain (range 1-10) and
bruising scores (range 1-5).
Results: A total of 164 procedures were evaluated.
Baseline characteristics did not differ across groups. Pain
scores did not differ between 810nm vs 980nm
(2.521.77 vs 2.751.84, P0.51), but they were signif-
icantly lower between 810nm vs 1320nm (2.521.77 vs
0.810.54, P0.0001) and 980nm vs 1320nm (P
0.0001). Similarly, bruising scores did not differ between
810nm vs 980nm (2.251.19 vs 2.061.45, P0.45),
but they were significantly lower between 810nm vs
1320nm (2.251.19 vs 0.820.47, P0.0001) and
980nm vs 1320nm (P0.0001).
Conclusions: This study demonstrates that the use of a
higher wavelength laser results in diminished post-proce-
dural pain and bruising. Moreover, the effect becomes
significant with use of the 1320nm wavelength.iuthor Disclosures: M. A. Adelman: Nothing to dis-
lose; T. Berland: Nothing to disclose; N. S. Cayne:
othing to disclose; C. Chasin: Nothing to disclose;
. R. Jacobowitz: Nothing to disclose; L. S. Kabnick:
othing to disclose; P. J. Lamparello: Nothing to
isclose; T. S. Maldonado: Nothing to disclose; C. B.
ockman: Nothing to disclose; M. Sadek: Nothing to
isclose.
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inlayson5, Jack L. Cronenwett1, Philip P. Goodney1.
Section of Vascular Surgery, Dartmouth-Hitchcock Med-
cal Center, Lebanon, NH; 2Department of Vascular and
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urgery and Endovascular Therapy, Emory University
chool of Medicine, Atlanta, GA; 4Section of Vascular
urgery, University of Florida College ofMedicine, Gaines-
ille, FL; 5Department of Surgery, Dartmouth-Hitchcock
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Objectives: Deep venous thrombosis (DVT) is a qual-
ty measure recorded by initiatives such as the National
urgical Quality Improvement Program (NSQIP). How-
ver, it is unclear how the manner in which the DVT was
iagnosed (symptomatic vs. surveillance) may affect this
easure.
Methods: Using the NSQIP database (2007-2008),
e compared DVT rates of vascular (amputation, open
ortic procedures, and lower extremity bypass (LEB)) and
on-vascular operations (prostatectomy, gastric bypass
GBP) and total hip arthroplasty (THA)). Using a pre-
efined literature search strategy, we compared the inci-
ence of DVT in NSQIP (DVT requiring treatment) to
eer reviewed literature incidence of DVT when diagnosed
y symptomatic status or when diagnosed by surveillance
tudies.
Results: Within NSQIP, the incidence of post-oper-
tive DVT varied from 0.3% after GBP, to 1.7% after
pen abdominal aortic surgery (Table). Across all proce-
ures except amputation, the incidence of DVT in
SQIP was similar to the incidence of DVT reported in
tudies of “symptomatic” patients. However, for all pro-
edures except GBP, the NSQIP DVT rate was dramat-
cally lower than the rate of DVT reported in surveillance
tudies.
Conclusions: The incidence of DVT reported in
SQIP is similar to reported incidence of symptomatic
VT, but remains lower than rates reported in surveil-
ance studies. To avoid inappropriate penalization of
enters that perform surveillance screening, better delin-
ation of symptomatic versus surveillance DVT is needed
n quality improvement registries.
